Swiss National Bank Has $17.97 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Swiss National Bank trimmed its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 7.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 54,700 shares of the medical research company's stock after selling 4,400 shares during the quarter. Swiss National Bank owned 0.20% of Bio-Rad Laboratories worth $17,969,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the business. HighTower Advisors LLC boosted its position in shares of Bio-Rad Laboratories by 3.9% in the fourth quarter. HighTower Advisors LLC now owns 6,250 shares of the medical research company's stock valued at $2,053,000 after acquiring an additional 237 shares during the period. Wealthfront Advisers LLC bought a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at approximately $342,686,000. Moran Wealth Management LLC boosted its position in shares of Bio-Rad Laboratories by 3.4% in the fourth quarter. Moran Wealth Management LLC now owns 2,429 shares of the medical research company's stock valued at $798,000 after acquiring an additional 80 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Bio-Rad Laboratories by 67.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,588 shares of the medical research company's stock valued at $3,478,000 after acquiring an additional 4,256 shares during the period. Finally, Larson Financial Group LLC boosted its position in shares of Bio-Rad Laboratories by 11.6% in the fourth quarter. Larson Financial Group LLC now owns 1,143 shares of the medical research company's stock valued at $375,000 after acquiring an additional 119 shares during the period. 65.24% of the stock is owned by institutional investors.

Remove Ads

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock traded up $1.95 during mid-day trading on Friday, hitting $256.42. 1,439,995 shares of the company were exchanged, compared to its average volume of 289,974. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The business has a fifty day moving average of $303.23 and a 200 day moving average of $325.34. Bio-Rad Laboratories, Inc. has a 1-year low of $244.00 and a 1-year high of $387.99. The company has a market capitalization of $7.18 billion, a PE ratio of -3.94 and a beta of 0.98.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analyst Weigh In

BIO has been the subject of several research reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $481.00 target price on shares of Bio-Rad Laboratories in a research report on Tuesday, January 14th. StockNews.com cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research report on Monday, February 17th. Finally, Wells Fargo & Company reduced their target price on Bio-Rad Laboratories from $360.00 to $345.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories currently has a consensus rating of "Moderate Buy" and a consensus price target of $395.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.